Perspective

Using Bronchiectasis Action Management Plans for Children With Bronchiectasis—Can It Improve Clinical Care?

Kobi L. Schutz, Julie M. Marchant, Anne B. Chang, Catherine Turner, Mark D. Chatfield, Gabrielle B. McCallum

Research output: Contribution to journalArticleResearchpeer-review

Abstract

While once thought to be rare, bronchiectasis has been increasing globally over the last 15 years. Bronchiectasis is a major contributor to chronic lung morbidity and mortality but remains a neglected disease in respiratory health globally. Currently, few high-level evidence-based management strategies are available for children with bronchiectasis. Strategies to improve clinical outcomes associated with exacerbations are important. In other respiratory conditions such as asthma and chronic obstructive pulmonary disease, use of personalized written management plans have been shown to improve clinical outcomes. Personalized management plans have also been recommended as part of treatment plans in adults with bronchiectasis. We thus undertook a review of the current literature to determine available evidence, and to establish whether a personalized written bronchiectasis action management plan (BAMP) improves clinical outcomes in children with bronchiectasis. Our search identified 43 articles; 16 duplicates were removed and a further 23 were excluded on titles and abstracts alone. Four full-text articles were reviewed but excluded. In the absence of any published studies, it remains unknown whether the use of BAMP is beneficial for improving clinical outcomes for children with bronchiectasis. These results have highlighted this clinical gap and identified the need for high-quality research to inform practice. Until high-quality evidence is available, clinicians are advised to adhere to current national and/or international guidelines.

Original languageEnglish
Article number428
JournalFrontiers in Pediatrics
Volume7
DOIs
Publication statusPublished - 30 Oct 2019

Fingerprint

Bronchiectasis
Neglected Diseases
Chronic Obstructive Pulmonary Disease
Asthma
Guidelines
Morbidity
Lung
Mortality
Health
Research

Cite this

@article{8ae1ab5729e4425c891b33a307dd0cdb,
title = "Perspective: Using Bronchiectasis Action Management Plans for Children With Bronchiectasis—Can It Improve Clinical Care?",
abstract = "While once thought to be rare, bronchiectasis has been increasing globally over the last 15 years. Bronchiectasis is a major contributor to chronic lung morbidity and mortality but remains a neglected disease in respiratory health globally. Currently, few high-level evidence-based management strategies are available for children with bronchiectasis. Strategies to improve clinical outcomes associated with exacerbations are important. In other respiratory conditions such as asthma and chronic obstructive pulmonary disease, use of personalized written management plans have been shown to improve clinical outcomes. Personalized management plans have also been recommended as part of treatment plans in adults with bronchiectasis. We thus undertook a review of the current literature to determine available evidence, and to establish whether a personalized written bronchiectasis action management plan (BAMP) improves clinical outcomes in children with bronchiectasis. Our search identified 43 articles; 16 duplicates were removed and a further 23 were excluded on titles and abstracts alone. Four full-text articles were reviewed but excluded. In the absence of any published studies, it remains unknown whether the use of BAMP is beneficial for improving clinical outcomes for children with bronchiectasis. These results have highlighted this clinical gap and identified the need for high-quality research to inform practice. Until high-quality evidence is available, clinicians are advised to adhere to current national and/or international guidelines.",
keywords = "action plan, bronchiectasis, children, clinical trials, management plan, randomized controlled trials",
author = "Schutz, {Kobi L.} and Marchant, {Julie M.} and Chang, {Anne B.} and Catherine Turner and Chatfield, {Mark D.} and McCallum, {Gabrielle B.}",
year = "2019",
month = "10",
day = "30",
doi = "10.3389/fped.2019.00428",
language = "English",
volume = "7",
journal = "Frontiers in Pediatrics",
issn = "2296-2360",
publisher = "Frontiers Research Foundation",

}

Perspective : Using Bronchiectasis Action Management Plans for Children With Bronchiectasis—Can It Improve Clinical Care? / Schutz, Kobi L.; Marchant, Julie M.; Chang, Anne B.; Turner, Catherine; Chatfield, Mark D.; McCallum, Gabrielle B.

In: Frontiers in Pediatrics, Vol. 7, 428, 30.10.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Perspective

T2 - Using Bronchiectasis Action Management Plans for Children With Bronchiectasis—Can It Improve Clinical Care?

AU - Schutz, Kobi L.

AU - Marchant, Julie M.

AU - Chang, Anne B.

AU - Turner, Catherine

AU - Chatfield, Mark D.

AU - McCallum, Gabrielle B.

PY - 2019/10/30

Y1 - 2019/10/30

N2 - While once thought to be rare, bronchiectasis has been increasing globally over the last 15 years. Bronchiectasis is a major contributor to chronic lung morbidity and mortality but remains a neglected disease in respiratory health globally. Currently, few high-level evidence-based management strategies are available for children with bronchiectasis. Strategies to improve clinical outcomes associated with exacerbations are important. In other respiratory conditions such as asthma and chronic obstructive pulmonary disease, use of personalized written management plans have been shown to improve clinical outcomes. Personalized management plans have also been recommended as part of treatment plans in adults with bronchiectasis. We thus undertook a review of the current literature to determine available evidence, and to establish whether a personalized written bronchiectasis action management plan (BAMP) improves clinical outcomes in children with bronchiectasis. Our search identified 43 articles; 16 duplicates were removed and a further 23 were excluded on titles and abstracts alone. Four full-text articles were reviewed but excluded. In the absence of any published studies, it remains unknown whether the use of BAMP is beneficial for improving clinical outcomes for children with bronchiectasis. These results have highlighted this clinical gap and identified the need for high-quality research to inform practice. Until high-quality evidence is available, clinicians are advised to adhere to current national and/or international guidelines.

AB - While once thought to be rare, bronchiectasis has been increasing globally over the last 15 years. Bronchiectasis is a major contributor to chronic lung morbidity and mortality but remains a neglected disease in respiratory health globally. Currently, few high-level evidence-based management strategies are available for children with bronchiectasis. Strategies to improve clinical outcomes associated with exacerbations are important. In other respiratory conditions such as asthma and chronic obstructive pulmonary disease, use of personalized written management plans have been shown to improve clinical outcomes. Personalized management plans have also been recommended as part of treatment plans in adults with bronchiectasis. We thus undertook a review of the current literature to determine available evidence, and to establish whether a personalized written bronchiectasis action management plan (BAMP) improves clinical outcomes in children with bronchiectasis. Our search identified 43 articles; 16 duplicates were removed and a further 23 were excluded on titles and abstracts alone. Four full-text articles were reviewed but excluded. In the absence of any published studies, it remains unknown whether the use of BAMP is beneficial for improving clinical outcomes for children with bronchiectasis. These results have highlighted this clinical gap and identified the need for high-quality research to inform practice. Until high-quality evidence is available, clinicians are advised to adhere to current national and/or international guidelines.

KW - action plan

KW - bronchiectasis

KW - children

KW - clinical trials

KW - management plan

KW - randomized controlled trials

UR - http://www.scopus.com/inward/record.url?scp=85075257353&partnerID=8YFLogxK

U2 - 10.3389/fped.2019.00428

DO - 10.3389/fped.2019.00428

M3 - Article

VL - 7

JO - Frontiers in Pediatrics

JF - Frontiers in Pediatrics

SN - 2296-2360

M1 - 428

ER -